Important Notice for Neumora Therapeutics, Inc. (NMRA) Shareholders: A Legal Perspective
NEW YORK, March 06, 2025 – The Gross Law Firm, a leading securities fraud law firm, is taking action on behalf of investors in Neumora Therapeutics, Inc. (NMRA) following recent allegations of potential securities fraud. If you purchased or otherwise acquired Neumora securities between January 1, 2023, and February 28, 2025, you may be eligible to participate in this class action.
Background:
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological disorders. The company’s lead product candidate, NM-001, is a novel, proprietary, orally-administered therapeutic for the treatment of Alzheimer’s disease.
Allegations:
The Gross Law Firm alleges that Neumora Therapeutics, Inc. and certain of its executives and directors made false and misleading statements regarding the company’s business, operational, and financial results. Specifically, it is alleged that the company downplayed the risks associated with its clinical trials and overstated the prospects for NM-001.
Impact on Shareholders:
If the allegations are proven, Neumora Therapeutics, Inc. shareholders may be able to recover their losses. The Gross Law Firm is seeking to recover damages on behalf of all affected investors. Eligible shareholders are encouraged to contact the firm as soon as possible to discuss their legal options.
Impact on the World:
The potential impact of this situation goes beyond Neumora Therapeutics, Inc. and its shareholders. If proven, the allegations could have broader implications for the biotechnology industry as a whole. It could lead to increased scrutiny of clinical trial data and reporting practices, potentially impacting investor confidence and the ability of companies to raise capital.
Next Steps:
If you purchased or otherwise acquired Neumora Therapeutics, Inc. securities between January 1, 2023, and February 28, 2025, you may be eligible to participate in this class action. We encourage you to contact The Gross Law Firm as soon as possible to discuss your legal options. There is no cost or obligation to you.
- Call 888-223-7176
- Email [email protected]
- Visit www.grossclassaction.com/neumora to learn more
The Gross Law Firm represents investors worldwide, and the firm’s securities fraud litigation spans over four decades. The firm takes pride in providing exemplary client service and legal expertise.
Conclusion:
Investors in Neumora Therapeutics, Inc. who purchased or otherwise acquired securities between January 1, 2023, and February 28, 2025, may be eligible to participate in a class action lawsuit alleging securities fraud. The Gross Law Firm is seeking to recover damages on behalf of all affected investors. If the allegations are proven, it could have broader implications for the biotechnology industry. Shareholders are encouraged to contact The Gross Law Firm as soon as possible to discuss their legal options.
Contact us today to learn more: Call 888-223-7176, email [email protected], or visit www.grossclassaction.com/neumora.
